바이젠셀

308080KOSDAQ자연과학 및 공학 연구개발업

47.3 / 100

Reference Date: 2026-04-13

Financial Score13.0 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Declined 12.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Bizen Cell is a biotech venture company established in 2013, specializing in the development and manufacturing of immunotherapy drugs. Leveraging its HLA research expertise and utilizing umbilical cord blood-derived immune therapies, the company is advancing as a cell therapy specialist through pipelines such as ViTier and ViMedier, while expanding into global new drug development and advanced regenerative medicine.

Number of Employees

43people

Average Salary

86.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-32.09Industry Average -32.113.5Point

Below industry avg

Debt Ratio

20.24Industry Average 7.520.0Point

2.7x industry avg (risky)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (1-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -25.3% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
[클리니컬 히스토리] 바이젠셀, 2상 데이터 中 직행…LO 성사 분수령
바이젠셀은 임상 2상 무질병생존율(DFS) 데이터를 바탕으로 중국에서 리딩 파이프라인 VT-EBV-N의 기술이전(LO) 협상 속도를 높이고 있으며, 이는 기업 가치의 분수령이 될 것으로 전망됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 5,340Won52-week high 15,80052-week low 2,805

1-month return1.0Point

1m -12.32% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-03-31
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-31
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18